[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370731-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-370731-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","health-impact-of-using-anti-pd-l1-agents-to-treat-early-stage-cancers-in-switzerland-a-modeling-study","Health impact of using anti-PD-(L)1 agents to treat early-stage cancers in Switzerland - a modeling study","","Health outcomes projection model evaluates introducing anti-PD-(L)1 agents in neoadjuvant/adjuvant regimens for early-stage cancers in Switzerland versus reserving them for advanced or metastatic disease. The model compares two 10-year scenarios and focuses on melanoma, renal cell carcinoma, and triple-negative breast cancer. Estimated endpoints include life-years, QALYs, recurrences/events, metastatic active treatments, adverse events, and deaths. Results indicate fewer recurrences, fewer metastatic treatments, fewer deaths, and increased life-years without recurrence with earlier use.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/health-impact-of-using-anti-pd-l1-agents-to-treat-early-stage-cancers-in-switzerland-a-modeling-study/370731/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/health-impact-of-using-anti-pd-l1-agents-to-treat-early-stage-cancers-in-switzerland-a-modeling-study/370731.png","ImageObject",300,407,{"name":42,"@type":43},"Cart","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"Which cancers are included in the 10-year health outcomes projection model?","Question",{"text":63,"@type":64},"The model evaluates melanoma, renal cell carcinoma, and triple-negative breast cancer (TNBC) in Switzerland over a 10-year period.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What are the two treatment scenarios compared in the modeling study?",{"text":68,"@type":64},"Scenario I uses anti-PD-(L)1 agents only for advanced/metastatic disease, while Scenario II starts anti-PD-(L)1 agents in the neoadjuvant/adjuvant setting for early-stage cancers.",{"name":70,"@type":61,"acceptedAnswer":71},"What key outcomes were estimated in the study?",{"text":72,"@type":64},"Estimated outcomes include life-years, quality-adjusted life-years (QALYs), recurrences/events, active metastatic treatments, adverse events, and deaths.",{"name":74,"@type":61,"acceptedAnswer":75},"What does the model predict about health impact when anti-PD-(L)1 agents are used earlier?",{"text":76,"@type":64},"Earlier use in neoadjuvant and/or adjuvant settings is projected to avoid recurrences, prevent active metastatic treatments, reduce deaths, and increase life-years without recurrence compared with metastatic-only use.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},370731,1790469976,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":119,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":148,"preview_page_count":33,"preview_urls":149},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","TYPE Original Research PUBLISHED 03 July 2025  \nDOI 10.3389/fimmu.2025.1601377  \nOPEN ACCESS  \nEDITED BY  \nClaude Lambert,  \nCentre Hospitalier Universitaire (CHU) de Saint-E´tienne, France  \nREVIEWED BY  \nBiljana Bufan,  \nUniversity of Belgrade, Serbia Jorge J. Nieva,  \nUniversity of Southern California, United States  \n*CORRESPONDENCE  \nAndrea Favre-Bulle  \n [andrea.favre-bulle.pantoja@msd.com](andrea.favre-bulle.pantoja@msd.com)  \nRECEIVED 28 March 2025  \nACCEPTED 05 June 2025  \nPUBLISHED 03 July 2025  \nCITATION  \nFavre-Bulle A, Stanković M, Mantaian T, Frei C, Schaefer S, Gabriel SS, Sönmez D and Aguiar-Ibáñez R (2025) Health impact of using anti-PD-(L)1 agents to treat early-stage cancers in Switzerland: a modeling study.  \nFront. Immunol. 16:1601377 .  \ndoi: 10.3389/fimmu.2025.1601377  \nCOPYRIGHT  \n© 2025 Favre-Bulle, Stanković, Mantaian, Frei, Schaefer, Gabriel, Sönmez and Aguiar-Ibáñez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nHealth impact of using anti-PD (L)1 agents to treat early-stage cancers in Switzerland:  \na modeling study  \nAndrea Favre-Bulle 1*, Maja Stanković1, Tyler Mantaian 2, Claudia Frei 3, Sonja Schaefer 4, Sarah Sharon Gabriel 3, Demet Sönmez 5 and Raquel Aguiar-Ibáñez 6  \n1Global Human Health, MSD, Lucerne, Switzerland, 2 Lumanity, Bethesda, MD, United States, 3Global Medical and Scientiﬁc Affairs, MSD, Lucerne, Switzerland, 4 European Clinical Development, Oncology, MSD, Zurich, Switzerland, 5Global Medical and Scientiﬁc Affairs, MSD, Stockholm, Sweden, 6 Merck Canada, Inc., Kirkland, QC, Canada  \nBackground: Inhibitors of programmed cell death protein 1 (PD-1) and its ligand (PD-L1) (referred to hereafter as anti-PD-(L)1 agents) are approved to treat a variety of advanced-stage cancers. Incorporating these agents into neoadjuvant/ adjuvant treatment regimens for early-stage cancers may provide health and economic beneﬁts at the population level.  \nMethods: A health outcomes projection model compared two scenarios in Switzerland: I) anti-PD-(L)1 agents used only for advanced/metastatic disease, and II) anti-PD-(L)1 agents starting in the neoadjuvant/adjuvant setting. The model focused on three cancers for which anti-PD-(L)1 agents are currently approved in Europe in early stages: melanoma, renal cell carcinoma (RCC), and triple-negative breast cancer (TNBC), projecting clinical evolution over 10 years. Estimated outcomes included life-years, quality-adjusted life-years (QALYs), recurrences/ events, active treatments for metastatic disease, adverse events, and deaths.  \nResults: Of the estimated 10,659 eligible patients during 2022-2031, 9,050 were predicted to initiate neoadjuvant and/or adjuvant treatment with anti-PD-(L)1 agents for treatment of melanoma, RCC, or TNBC. Compared to anti-PD-(L)1 agents being available only in the metastatic setting, use of anti-PD-(L)1 agents in the neoadjuvant and/or adjuvant setting for these 3 cancers was projected to avoid 1,144 recurrences (a 27% decrease), prevent 1,577 active treatments in the metastatic setting (a 35% decrease), avoid 530 deaths (a 23% decrease), and increase life-years without recurrence by 3,416 (a 10% increase) .  \nConclusion: The use of anti-PD(L)1 agents to treat early-stage cancers in Switzerland is anticipated to result in better outcomes by preventing recurrences/events, active metastatic treatments, and deaths.  \nKEYWORDS  \nimmune checkpoint inhibitors, melanoma, nivolumab, pembrolizumab, renal cell carcinoma, triple-negative breast cancer  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nEarly de","cbCaisJNq8ZHAYwb","https://ap.wps.com/l/cbCaisJNq8ZHAYwb","pdf",655969,"English","# Background\n# Methods\n## 2.1 Description\n# Results\n# Conclusion","[{\"question\":\"Which cancers are included in the 10-year health outcomes projection model?\",\"answer\":\"The model evaluates melanoma, renal cell carcinoma, and triple-negative breast cancer (TNBC) in Switzerland over a 10-year period.\"},{\"question\":\"What are the two treatment scenarios compared in the modeling study?\",\"answer\":\"Scenario I uses anti-PD-(L)1 agents only for advanced/metastatic disease, while Scenario II starts anti-PD-(L)1 agents in the neoadjuvant/adjuvant setting for early-stage cancers.\"},{\"question\":\"What key outcomes were estimated in the study?\",\"answer\":\"Estimated outcomes include life-years, quality-adjusted life-years (QALYs), recurrences/events, active metastatic treatments, adverse events, and deaths.\"},{\"question\":\"What does the model predict about health impact when anti-PD-(L)1 agents are used earlier?\",\"answer\":\"Earlier use in neoadjuvant and/or adjuvant settings is projected to avoid recurrences, prevent active metastatic treatments, reduce deaths, and increase life-years without recurrence compared with metastatic-only use.\"}]","Health impact of using anti-PD-(L)1 agents to treat early-stage cancers in Switzerland - a modeling study | PDF",1790190117,23,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6851a7dc5b48e89331f761e71471aeea.webp",983,1389,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dbf8fbe91309c0ca6d5ba11f3a95e4a5.webp",982,1388,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/51d60ad10af42b7a7ba4adbf4ca2e36e.webp",981,1386,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e7fd8fe51707ea9202fe19f0b3ed3b1.webp",980,1385]